Bristol-Myers Squibb receives positive opinion from CHMP for Opdivo for advanced melanoma

April 24, 2015 11:28 AM

13 0

24 April 2015  •  Author: Victoria White

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, be granted approval for use in both first-line and previously treated patie...

Read more

To category page